November 5, 2020
AstraZeneca’s olaparib + bevacizumab cleared as certain cancer treatment in EU
AstraZeneca and MSD’s Lynparza (olaparib) has been approved in the European Union (EU) for the 1st-line maintenance treatment with bevacizumab of patients with homologous recombination deficient (HRD)-positive advanced ovarian cancer.